NCT04458545View on ClinicalTrials.gov

Clinical Trials of Multivalent Opioid Vaccine Components

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

October 8, 2020

Primary Completion Date

March 30, 2026

Study Completion Date

March 30, 2026

Conditions
Opioid-use Disorder
Interventions
BIOLOGICAL

Oxy(Gly)4-sKLH vaccine - Low Dose

Oxy(Gly)4-sKLH vaccine - Low Dose

BIOLOGICAL

Oxy(Gly)4-sKLH vaccine - High Dose

Oxy(Gly)4-sKLH vaccine - high dose

BIOLOGICAL

Placebo Oxy(Gly)4-sKLH vaccine

Oxy(Gly)4-sKLH vaccine - Placebo

Trial Locations (2)

10032

ACTIVE_NOT_RECRUITING

New York State Psychiatric Institute: Division on Substance Use Disorders, New York

07724

RECRUITING

Clinilabs Drug Development Corporation, Eatontown

Sponsors

Collaborators (1)

Clinilabs, Inc.
All Listed Sponsors
collaborator

Clinilabs, Inc.

OTHER

collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

New York State Psychiatric Institute

OTHER

NCT04458545 - Clinical Trials of Multivalent Opioid Vaccine Components | Biotech Hunter | Biotech Hunter